Clarity Pharmaceuticals ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with ...

An update from Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) is now available. Clarity Pharmaceuticals announced that data from its Phase II Co-PSMA ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation ...

MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, ...

MELBOURNE, Australia and INDIANAPOLIS, /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix') today ...

Background: Comparative patient dosimetry for diagnostic PET/CT can guide radiation-safety procedures and tracer selection in prostate cancer. We compared [^68Ga]Ga-PSMA-11 and ^18F-choline PET/CT and ...

Background: Head and neck paragangliomas (HNPGs) are rare neuroendocrine tumors originating from neural crest cells, with some exhibiting malignant potential. Traditional imaging modalities, such as ...

MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Centers for ...

The FDA has expanded the label for gallium Ga-68 gozetotide (Illuccix) to include patient selection for radioligand therapy (RLT) in the pretaxane setting for metastatic castration-resistant prostate ...

Illuccix, a preparation kit for injectable Ga-68, has been approved to select patients for radioligand therapy before taxane chemotherapy. The FDA has approved a label expansion for Illuccix to ...